The bill, HB 648-FN, mandates that health insurance providers cover glucose monitoring devices and supplies for individuals diagnosed with diabetes, ensuring that both individual and group accident or health insurance policies include coverage for medically necessary outpatient self-management training, educational services, and diabetes-related equipment. Key provisions include a cap of $30 on copayments for each 30-day supply of prescription insulin drugs, which will not be subject to any deductible. The bill also requires insurers to cover glucose monitoring devices and supplies without imposing deductibles and eliminates the need for prior authorization or referrals for endocrinology services.

Additionally, the legislation stipulates that recipients must participate in follow-up care with their healthcare practitioners at specified intervals to maintain coverage. This follow-up is designed to assess the effectiveness of the monitoring devices in managing diabetes. The bill includes various insertions to expand coverage and clarify definitions related to diabetes treatment while deleting certain language to streamline requirements. Overall, HB 648-FN aims to improve access to essential diabetes management tools and services, although it may lead to increased insurance premiums due to anticipated rises in claims costs.

Statutes affected:
Introduced: 415:6-e, 415:18-f, 420-A:17-a, 420-B:8-k
HB648 text: 415:6-e, 415:18-f, 420-A:17-a, 420-B:8-k